| Original language | English (US) |
|---|---|
| Pages (from-to) | 255-258 |
| Number of pages | 4 |
| Journal | Leukemia |
| Volume | 35 |
| Issue number | 1 |
| DOIs | |
| State | Published - Jan 2021 |
ASJC Scopus subject areas
- Hematology
- Oncology
- Cancer Research
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
In: Leukemia, Vol. 35, No. 1, 01.2021, p. 255-258.
Research output: Contribution to journal › Article › peer-review
}
TY - JOUR
T1 - Phase 1 study of the anti-BCMA antibody-drug conjugate AMG 224 in patients with relapsed/refractory multiple myeloma
AU - Lee, Hans C.
AU - Raje, Noopur S.
AU - Landgren, Ola
AU - Upreti, Vijay V.
AU - Wang, Jin
AU - Avilion, Ariel A.
AU - Hu, Xuguang
AU - Rasmussen, Erik
AU - Ngarmchamnanrith, Gataree
AU - Fujii, Hisaki
AU - Spencer, Andrew
N1 - Funding Information: Conflict of interest HCL: research support and consultant/advisor (Amgen, Celgene, Janssen, and Takeda), consultant/advisor (Glax-oSmithKline and Sanofi), and research support (Daiichi Sankyo). NSR: consultant (Amgen Inc., Takeda, Celgene, Bristol-Myers Squibb, Janssen, Bluebird, and Karyopharm). OL: research funding (National Institutes of Health, U.S. Food and Drug Administration, Multiple Myeloma Research Foundation, International Myeloma Foundation, Leukemia and Lymphoma Society, Perelman Family Foundation, Rising Tide Foundation, Amgen Inc., Celgene, Janssen, Takeda, Glenmark, Seattle Genetics, and Karyopharm); honoraria and advisory boards (Adaptive, Amgen Inc., Binding Site, Bristol-Myers Squibb, Celgene, Cellectis, Glenmark, Janssen, Juno, Pfizer); and Independent Data Monitoring Committees (Takeda, Merck, and Janssen). VVU, JW, AAA, XH, ER, GN, and HF: employment by and stock ownership in Amgen Inc. AS: consultant (Celgene, Janssen, Secura Bio, Specialised Therapeutics Australia, AbbVie, Servier, HaemaLogiX, and Sanofi); speaker’s bureau (Celgene, Janssen, and Takeda); grant/Research Support (Celgene, Janssen, Amgen Inc., Takeda, Servier, HaemaLogiX); honoraria (Celgene, Janssen, Amgen Inc., Takeda, Secura Bio, Specialised Therapeutics Australia, AbbVie, Servier, HaemaLogiX, and Sanofi).
PY - 2021/1
Y1 - 2021/1
UR - http://www.scopus.com/inward/record.url?scp=85083712561&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85083712561&partnerID=8YFLogxK
U2 - 10.1038/s41375-020-0834-9
DO - 10.1038/s41375-020-0834-9
M3 - Article
C2 - 32317775
AN - SCOPUS:85083712561
SN - 0887-6924
VL - 35
SP - 255
EP - 258
JO - Leukemia
JF - Leukemia
IS - 1
ER -